Nitric Oxide: Biofilms Beware!

Catherine Harley

BY

hronic wounds of the lower extremity, as defined by showing no evidence of healing after a six- to 12-week period of best clinical practice;1 are a challenge to both health-care professionals and patients. Several factors can impact the normal healing process, including infection, the presence of necrotic tissue, impaired tissue perfusion and the use of steroids.² Research has shown that the presence of bacterial biofilm or critical colonizationwhich is a complex, organized network of bacteria and tenacious film that is difficult to treat with conventional antibiotics³-can also disrupt the normal healing process. Sharp debridement and topical antimicrobials are often used to deal with these biofilms, but they are often ineffective.4 Introduced gaseous nitric oxide (gNO) may provide a new option for eradicating these biofilms.⁵

Nitric oxide (NO) is a very small free-radical gas that has now been identified as a key secondary messenger molecule for many basic biochemical reactions within body systems. NO, as a result of various stimuli, is regulated by three nitric oxide synthases (cNOS, iNOS and eNOS) that are each responsible for various concentrations and the duration of NO produced. NO is synthesized in the presence of oxygen and calcium by cleaving a NO molecule off a precursor amino acid (L-arginine). The molecules of NO produced, because of their lipophilic nature and small size, readily pass through cell membranes. NO, acting as a secondary messenger molecule, reacts with chemical targets such as oxygen to form reactive oxygen/nitrogen species or enzymes containing heme or iron (Fe), resulting in the genesis of major cytokinetic activity.

For example, within the circulatory system, NO acts as a powerful and selective vasodilator by up-regulating cyclic guanosine monophospate (cGMP), which prevents the influx of calcium ions that results in smooth muscle relaxation-vasodilatation. These characteristics of NO have led to extensive human studies with inhaled gaseous NO and its approval as a drug for reversing pulmonary vasoconstriction for treating "blue baby syndrome." NO is also a neurotransmitter that helps in the processing of nerve signals as they cross synapses. Within the innate immune system, NO is produced by macrophages and neutrophils and plays a key role as a frontline non-specific antimicrobial agent against a wide variety of micro-organisms, including *continued on page 62*

Glossary of Terms

Angiogenesis: The growth of new blood vessels that restore blood flow to tissues after injury.
Amino Acids: Building blocks of proteins.
Biofilm: Micro-organisms that adhere to surfaces.
Guanosine monophospate: A nucleotide found in RNA.
L-arginine: A protein amino acid present in the proteins of all living beings.
Lipophilic: Having the ability to dissolve, be dissolved in, or absorb lipids (fats).
Macrophage: A type of white blood cell that ingests foreign material and plays a major role in the immune response to foreign invaders such as infectious organisms.
Neutrophil: A type of white blood cell that helps to kill micro-organisms in the blood.
Proline: An amino acid.

Catherine Harley,

RN, IIWCC, is the Associate Editor of Wound Care Canada and Executive Director of the Canadian Association for Enterostomal Therapy.



Ease the pain... Gentleheal®

Gentle, for fragile skin

Gentleheal dressings use Sensil[®] technology, a silicone coating that helps prevent sticking to the wound, and won't damage the peri-wound skin. This means less trauma and pain during dressing changes.

Absorbs and locks in exudate, even under compression

Gentleheal offers unprecedented fluid handling with a combination of polyacrylate and foam. Exulock[™] technology absorbs and locks in exudate, preventing maceration of peri-wound skin, even under compression dressings.

Longer wear time means fewer dressing changes

Gentleheal can be left in place for up to 7 days, so fewer dressing changes are required, which may also mean a cost savings.

Choose between *Gentleheal Standard*, *Gentleheal Extra* and *Gentleheal Secure (with bordered adhesive)*. With Gentleheal, you can ease the pain and frequency of dressing changes.

Atraumatic and Superabsorbent...Gentleheal.



1-800-396-6996 | 905-403-7000 www.medline.com

*Data on file.

©2006 Medline Industries, Inc. Exuderm and Medline are registered trademarks and OdorShield is a trademark of Medline Industries, Inc. bacteria and viruses. With so many roles, it is not surprising that NO is associated with the regulation of wound healing; in fact, when there is a lack of NO the normal wound-healing process is impaired.

The specific benefits of introduced nitric oxide gas in wound healing are associated with anti-microbial and anti-inflammation properties.^{6,7} Recently it has been suggested that availability of L-arginine resulting in NO synthesis is necessary for the proper cross-linking of collagen fibres to one another, via proline, to minimize scarring and maximize the tensile strength of healed tissue.⁸ Early research shows that NO may regulate gene expression, which can play an important role in the wound-healing process.⁹ At low levels, NO has an impact on keratinocyte proliferation, while at higher levels there is an inhibition of cellular proliferation and differentiation occurs. In addition to its antimicrobial properties, NO has been seen to play a role in angiogenesis (the formation of new blood vessels).¹⁰

Clinical case studies have shown that gaseous NO can be delivered nocturnally at home with good patient adherence. There have been no side effects noted for this treatment, and preliminary clinical studies demonstrate results that look promising. Clinical research with NO is in progress, and in the future you may see it as an adjunct therapy for non-healing, chronic wounds.

For further information on the use of nitric oxide in wound healing, visit www.baromedical.com/HBO2006/ handouts/Boykin-HBO_Nitrix_Oxide.pdf. "

References

- Kunimoto B, Cooling M, Gulliver W, Houghton P, Orsted H, Sibbald RG. Best practices for the prevention and treatment of venous leg ulcers. Ostomy/Wound Management. 2001;47(2):34-46,48-50.
- McCance KL, Heather SE. Pathophysiology: The Biologic Basis for Disease in Adults and Children, Third Edition. St. Louis: Mosby. 1998;232-234.
- Hannson C, Hoborn J, Moller A, Swanbeck G. The microbial flora in venous leg ulcers without clinical signs of infection. *Acta Dermato-Venerologica*. 1995;75:24-30.
- Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. The Lancet. 2001;358:135-138.
- Moncada S, Palmer RMJ, Higgis EA. Nitric oxide, physiology, pathophysiology and pharmacology. *Pharmacol Rev.* 1991;43:109-134.
- 6. Witte MB, Barubul A. Role of nitric oxide in wound repair. *The American Journal of Surgery*. 2002;183:406-412.
- 7. Fang FC. Mechanisms of nitric-oxide-related antimicrobial activity. *The Journal of Clinical Investigation*.1997;99(12):28128-2825.
- Barbul A, Fishel RS, Shimazu S, Wasserkrug HL, Yoshimura NN, Tao RC, Elron G. Intravenous hyperaliminatation with high arginine levels improves wound healing and immune function. *J Surg Res.* 1985;38:328-334.
- Wang R, Ghahary A, Shen YJ, Scott PG, Tredget EE. Human dermal fibroblasts produce nitric oxide and express both constitutive and inducible NOS isofoms. *J Invest Dermatol.* 1996;106:419-427.
- Hardwick JBJ, Tucker AT, Wilks M, Johnston A, Benjamin N. A novel method for the delivery of nitrous oxide therapy to the skin of human subjects using a semi-permeable membrane. *Chemical Science*. 2001;100:395-400.

Infection and Wound Care: A Critical Role for Prevention and Control *continued from page 43*

Hand-washing is the single most important infection prevention tool there is. Alcohol hand rinses have helped to decrease the amount of time it takes to clean hands, but the statistic remains that health-care workers only wash their hands 30 to 50 per cent of the time where it would be appropriate for them to do so.⁵ That is a scary number.

Do you see any future trends related to the infection control of wounds?

I think we will continue to see new antimicrobial dressings on the market, and hopefully resistance to these will not happen any time soon. However, when it does, we will have to look for other ways to manage microbes in our wounds.

References

- Apisarnthanarak A, Little JR. Skin and soft tissue infections. In Carrico R, (ed.). APIC Text of Infection Control and Epidemiology. Washington, DC: Association for Professionals in Infection Control and Epidemiology. 2005.
- Dow G. Bacterial swabs and the chronic wound: When, how, and what do they mean? Ostomy/Wound Management. 2003;49(5A):8-13.
- Cutting KF, White RJ. Criteria for identifying wound infection– Revisited. Ostomy/Wound Management. 2005;51(1):28-34.
- Block AJ. Reducing the risk of wound infections: Examining the role of antimicrobial resistance in the management of lower extremity infections. Ostomy/Wound Management. 2006;52(10) (Supplement).
- 5. Pittet D. Improving adherence to hand hygiene practice: A multidisciplinary approach. *Emerging Infectious Diseases*. 2001;7(2): 234-240.



THE HUNTLEIGH DOPPLERS: YOUR DIAGNOSTIC

TOOL TO SAFE COMPRESSION THERAPY

The Huntleigh Vascular Pocket dopplers are based on over 20 years experience in this field, the latest generation offers even greater performance, quality and value.

New improvments include:

- New probe design with 50% greater sensitivity
- New EZ8 wide beam probe for easy vessel detection
- · Increased audio performance and efficient battery management

PRODUCTS FOR FULL LEG, LOWER LEG & ARM

As an alternative to bandages or compression stockings, clinically proven **CircAid® Products** provide nonelastic, easily adjustable, gradient compression therapy for the treatment of **ulcers**, Venous Disease & Lymphedema.



PRODUITS PRODUCTS MANUF,/DISTR. J. VAILLANCOURT CORP./LTÉE/LTD 597 DUVERNAY ST, VERCHÈRES QC CANADA JOL 2RO TEL.: 1 800 361.3153 FAX: 1 888 583.6827 WWW.VALCO.CA



Targeting bacteria and **protecting the skin.**

Two advanced technologies. One antimicrobial dressing.

Only Mepilex[®] Ag combines the best of two superior technologies – the antimicrobial action of ionic silver with the benefits of Safetac[®] soft silicone technology.

- Inactivates pathogens within 30 minutes¹ of application and maintains sustained release action for up to 7 days²
- Safetac[®] soft silicone protects the peri-wound skin, reduces the risk of maceration and minimizes trauma and pain at dressing change^{3,4,5}
- Hydrophilic polyurethane foam in conjunction with a breathable outer film for optimal fluid handling
- Optimal odour control

For more information contact your Mölnlycke Health Care representative at 1-800-494-5134.

1,2 Data on file

Dykes, P.J., Heggie, R., and Hill, S.A. Effects of adhesive dressings on the stratum corneum of the skin. Journal of Wound Care, Vol. 10, No. 2, February 2001.
 Dykes, P.J. and Heggie, R. The link between the peel force of adhesive dressings and subjective discomfort in volunteer subjects. Journal of Wound Care, Vol. 12, No 7, July 2003.

5 Williams C. British Journal of Nursing. Vol 4, No 1, 1995.





